Avalon GloboCare Corp. (“Avalon” or the “Company”) , a diversified company focused on the development of precision diagnostic consumer products and the advancement of intellectual property in cellular therapy and generative AI publishing and software, announced that it received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b). Nasdaq further confirmed that the Company is now in compliance with all applicable continued listing standards.
Marketing Technology News: MarTech Interview with Michael McNeal, VP of Product at SALESmanago
As a result, the previously scheduled hearing before the Nasdaq Hearings Panel has been cancelled, and the Company’s common stock will continue to be listed and traded on the Nasdaq Capital Market.
Marketing Technology News: Complexity as a Cost Center: The Hidden Financial Burden of Fragmented Martech Stacks
“We are pleased to have regained compliance with Nasdaq’s minimum stockholders’ equity requirement, reflecting the progress we have made in strengthening our financial position and our continued focus on long-term shareholder value,” said Meng Li, Avalon’s Interim Chief Executive Officer and Chief Operating Officer. “With full Nasdaq compliance restored, we believe we are well positioned to execute on our growth initiatives, including launching marketing for our generative AI video platform, as well as expansion across precision diagnostics and strategic assets.”
Avalon GloboCare Corp. is a diversified company focused on the development of precision diagnostic consumer products and the advancement of intellectual property in cellular therapy, and generative artificial intelligence publishing and software through its Avalon Quantum AI, LLC subsidiary. Avalon is currently marketing the KetoAir breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAirTM is registered with the U.S. Food and Drug Administration as a Class I medical device. The Company also continues to focus on advancing its intellectual property portfolio through existing patent applications. In addition, Avalon owns and operates commercial real estate.
Write in to psen@itechseries.com to learn more about our exclusive editorial packages and programs.